Meta-analysis of ipilimumab in metastatic or locally advanced, unresectable melanoma

Share :
Published: 3 Oct 2013
Views: 6025
Prof Dirk Schadendorf - Universitätsklinikum Essen, Essen, Germany

Prof Dirk Schadendorf talks to ecancer at ECC 2013 about a meta-analysis of a collection of trials investigating ipilimumab.

By pooling all of the 1,800 patients analysed for long term survival, in addition to more than 2,000 patients in early access programmes, researchers were better able to understand the overall durability of the drug in melanoma.